Biotech layoffs in 2026: what is actually happening and what your skills are still worth.

Biotech in 2026 is in the third year of a brutal capital reset. Pre-clinical and early-clinical companies cut hardest first because the public markets stopped funding pre-revenue stories. Then late-clinical companies cut as readouts disappointed and follow-on rounds came in flat. By 2026, the layoffs are happening at companies that have approved drugs but cannot reach profitability — and at the contract research organisations that served all of them. What that means for you: the work is still real, the science is still real, and the demand for people who can run a clinical study or get a molecule through CMC has not disappeared. The companies have. Many of the strongest hiring stories right now are inside large pharma's late-stage pipelines, at the regulatory consultancies absorbing displaced clinical talent, and at the few well-capitalised platform companies still scaling. Industry conditions change rapidly — these notes reflect mid-2025 patterns and should be cross-referenced with current reporting.

What your skills are still worth

Your skills did not disappear with the role.

Clinical operations — running real studies, on time, with audit-ready data: Large pharma is hiring directly into clinical operations as CROs cut headcount. The same person who managed a Phase 2 study at a small biotech can run a Phase 3 site network inside a top-10 pharma — and the comp is often better. The interview loops are longer and more structured. Plan for six to ten weeks.
Regulatory affairs, especially CMC and post-approval: Regulatory has been the calmest function across the contraction. FDA's workload has not slowed, and companies that approved drugs in 2022–2024 are now in lifecycle work that requires regulatory bench depth. If you can write an IND or own a post-marketing commitment, your search is shorter than the average biotech worker's.
Manufacturing and CMC for cell and gene therapy: Even in a hard year, the small number of approved cell and gene therapies need scale-up, and the manufacturing problem is not solved. People who have done CMC for these modalities are scarce. The cuts have largely been at the discovery end of these companies, not at the manufacturing end.
Translational science with strong publication record: Pharma R&D is rebuilding internal translational teams that were outsourced during the lean years. PhDs and MDs who can sit between discovery and clinical — and who have published — are landing inside large pharma at higher levels than their previous biotech title.

Role-specific paths from here

Where each role goes next.

From: Clinical operations manager at a Series B biotech: Senior clinical trial manager at a top-20 pharma
Clinical operations role at an academic medical center running industry trials
Senior consultant at a clinical research consultancy (Parexel, ICON, IQVIA)
From: Research scientist at a discovery-stage biotech: Translational scientist at a large pharma's pre-clinical group
Senior scientist at a contract research organisation
Scientific role at a foundation-funded research institute (Broad, Whitehead, Salk)
From: Regulatory affairs associate at a small biotech: Regulatory affairs manager at a mid-cap pharma
Regulatory consultant at a specialised firm (PRA, Cato, NDA Group)
FDA reviewer (yes, this is a real path — federal hiring is open)

Questions

Common questions

Are biotech layoffs going to keep coming?

Probably yes through at least the next twelve months, then stabilising. The companies most exposed — pre-clinical and early-clinical with no near-term readouts — have largely already cut. The next wave will come from companies whose data disappoints or whose financings come in below expectations. By late 2026, the survivors will be hiring again.

Should I leave biotech entirely?

Most people who consider leaving biotech come back. The skills travel into healthcare more broadly — hospital systems, payers, healthtech, diagnostics — but the comp and the work are often less interesting than what biotech, even in a hard year, still offers. The exception is people who want stability over interesting work. Those move into pharma's larger, slower-moving operations.

Is consulting a good landing pad after a biotech layoff?

Often yes, especially for clinical operations and regulatory professionals. The big consultancies (ICON, IQVIA, Parexel, Syneos) have been hiring directly out of biotech layoffs because their clients still need bench depth. The hours are heavier, the work is similar, and the comp can be competitive. It is not a forever home for most people, but it is a strong six-to-eighteen-month bridge.

Your plan is built around what you tell us — not a template.

Start with a few questions. The plan follows.

Start your plan

Less than one session with a career coach.